REPLAY | Ozempic Should Be Cheap By Now. Here's Why It's Not

One drug. One molecule. 154 patents. That's not a typo — and in this replay episode of Bust Big Pharma, Rob Burgess explains exactly what it means for your pharmacy bill.Ozempic is the most talked-about drug in America right now. But behind the celebrity endorsements and the glossy TV ads is a story most people never hear: how Novo Nordisk built a legal fortress around a single molecule to keep cheaper competition off the market for years — and how much that delay is worth to them. The answer is $166 billion. Rob breaks down the patent thicketing playbook, why the GLP-1 market changes everything, and how Most Favored Nation pricing is the policy that Big Pharma is actually scared of.In this episode:What a patent thicket is — and why 154 patents around one drug should make every American angryThe $166 billion Novo Nordisk stands to collect by keeping generics out until 2031Why the GLP-1 market is projected to hit $100 billion a year — and what companies will do to protect thatHow real competition would drop prices 50-90% — and why it's being blockedWhy Americans pay $900-$1,300 a month for drugs that cost a fraction of that overseasMost Favored Nation pricing explained — and why Big Pharma fought it so hardThe bottom line: This isn't just an Ozempic story. It's a playbook. And once you see how it works, you start seeing it everywhere.🔔 New episodes every week — subscribe so you don't miss one.🌐 Get involved at BustBigPharma.com